AG
BDTX icon

Artal Group’s Black Diamond Therapeutics BDTX Stock Holding History

Artal Group’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,046,517
Closed -$4.88M – 13
2024
Q2 		$4.88M Hold
1,046,517
– – 0.12% 56
2024
Q1 		$5.31M Sell
1,046,517
-1,000,000
-49% -$4.03M 0.14% 61
2023
Q4 		$5.75M Hold
2,046,517
– – 0.19% 47
2023
Q3 		$5.87M Hold
2,046,517
– – 0.25% 54
2023
Q2 		$10.3M Buy
2,046,517
+400,000
+24% +$817K 0.32% 47
2023
Q1 		$3.11M Hold
1,646,517
– – 0.18% 72
2022
Q4 		$2.96M Hold
1,646,517
– – 0.17% 75
2022
Q3 		$2.78M Hold
1,646,517
– – 0.12% 79
2022
Q2 		$4.05M Hold
1,646,517
– – 0.22% 64
2022
Q1 		$4.56M Hold
1,646,517
– – 0.19% 84
2021
Q4 		$8.78M Hold
1,646,517
– – 0.24% 72
2021
Q3 		$13.9M Hold
1,646,517
– – 0.31% 69
2021
Q2 		$20.1M Hold
1,646,517
– – 0.41% 55
2021
Q1 		$39.9M Hold
1,646,517
– – 0.71% 30
2020
Q4 		$52.8M Buy
1,646,517
+125,000
+8% +$4.11M 1.13% 25
2020
Q3 		$46M Sell
1,521,517
-25,000
-2% -$761K 1.12% 20
2020
Q2 		$65.2M Sell
1,546,517
-150,000
-9% -$5.52M 1.82% 12
2020
Q1 		$42.3M Buy
+1,696,517
New +$51.6M 1.79% 16

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Artal Group's BDTX Position: Q3 2024 in Review

Artal Group sold out of Black Diamond Therapeutics (BDTX) in Q3 2024, closing a stake of 1,046,517 shares — an estimated $4.88M sold.

Artal Group first reported a position in BDTX in Q1 2020 and held it in 18 quarters. The position peaked at $65.2M in Q2 2020. 96 funds tracked by Wall St. Rank hold BDTX as of Q3 2024.

  • Artal Group reported no remaining Black Diamond Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 1,046,517 Black Diamond Therapeutics shares in Q3 2024, an estimated $4.88M.
  • Artal Group first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 18 quarters.
  • Artal Group's Black Diamond Therapeutics position peaked at $65.2M in Q2 2020.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.